ArticleAnnals of dermatology2015
Tranexamic Acid Diminishes Laser-Induced Melanogenesis.
Article in Annals of dermatology, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 62 citations in OpenAlex.
- Comparative study of different treatment modalities for melasma: introducing a novel nanotechnology-based tranexamic acid microemulsion.Archives of dermatological research · 2025Trial
- Trial
- Efficacy and Safety of Plasma Radiofrequency Combined With Topical Tranexamic Acid for Early Post-Traumatic Scars With Hyperpigmentation: A Retrospective Study.Journal of cosmetic dermatology · 2026Article
- Over-Represented Senescent Keratinocytes in Hyperpigmented Spots Promote Melanocyte Activation via IGFBP3 and NGF.International journal of molecular sciences · 2025Article
- A Novel Peel to Prevent Post-Inflammatory Hyperpigmentation After COJournal of cosmetic dermatology · 2025Article
- Oral tranexamic acid, low-fluence intense pulsed light, and glycolic acid for the treatment of mixed melasma: An observational study.Medicine · 2025Observational
- Usage Frequency and Ecotoxicity of Skin Depigmenting Agents.Pharmaceuticals (Basel, Switzerland) · 2025Article
- Low-Fluence Q-Switch 1064 Nm Laser Combined With Oral Tranexamic Acid: A Quicker Treatment for Laser-Induced Postinflammatory Hyperpigmentation.Journal of cosmetic dermatology · 2025Observational
- Use of Tranexamic Acid in SARS-COV-2: Boon or Bane?Archives of Razi Institute · 2024Review
- Tranexamic Acid for the Treatment of Hyperpigmentation and Telangiectatic Disorders Other Than Melasma: An Update.Clinical, cosmetic and investigational dermatology · 2024Review
- Comparative Studies on the Photoreactivity, Efficacy, and Safety of Depigmenting Agents.Pharmaceuticals (Basel, Switzerland) · 2023Article
- Review of Laser Treatments for Post-Inflammatory Hyperpigmentation in Skin of Color.American journal of clinical dermatology · 2023Review
- Review
- New oral and topical approaches for the treatment of melasma.International journal of women's dermatology · 2019Article
- Evaluation of Therapeutic Efficacy and Safety of Tranexamic Acid Local Infiltration in Combination with Topical 4% Hydroquinone Cream Compared to Topical 4% Hydroquinone Cream Alone in Patients with Melasma: A Split-Face Study.Dermatology research and practice · 2018Article
- Trabectedin is a promising antitumor agent potentially inducing melanocytic differentiation for clear cell sarcoma.Cancer medicine · 2017Article
- Tranexamic Acid and Supportive Measures to Treat Wasting Marmoset Syndrome.Comparative medicine · 2016Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 4 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThe treatment of post-inflammatory hyperpigmentation (PIH) remains challenging. Tranexamic acid, a well-known anti-fibrinolytic drug, has recently demonstrated a curative effect towards melasma and ultraviolet-induced PIH in Asian countries. However, the precise mechanism of its inhibitory effect on melanogenesis is not fully understood.
objectiveIn order to clarify the inhibitory effect of tranexamic acid on PIH, we investigated its effects on mouse melanocytes (i.e., melan-a cells) and human melanocytes.
methodsMelan-a cells and human melanocytes were cultured with fractional CO2 laser-treated keratinocyte-conditioned media. Melanin content and tyrosinase activity were evaluated in cells treated with or without tranexamic acid. Protein levels of tyrosinase, tyrosinase-related protein (TRP)-1, and TRP-2 were evaluated in melan-a cells. Signaling pathway molecules involved in melanogenesis in melanoma cells were also investigated.
resultsTranexamic acid-treated melanocytes exhibited reduced melanin content and tyrosinase activity. Tranexamic acid also decreased tyrosinase, TRP-1, and TRP-2 protein levels. This inhibitory effect on melanogenesis was considered to be involved in extracellular signal-regulated kinase signaling pathways and subsequently microphthalmia-associated transcription factor degradation.
conclusionTranexamic acid may be an attractive candidate for the treatment of PIH.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.